Abbott Laboratories (ABT)

Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date.

In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed OpenAI's ChatGPT and business applications.

On January 23, Evercore ISI trimmed its price target on Abbott Laboratories (NYSE:ABT) to $138 from $144. However, it kept an Outperform rating.

Savita Subramanian, the firm’s head of US equity and quant strategy, pointed to a familiar timing pattern. Dividend growth typically trails earnings growth by roughly three quarters.

Operator: Good morning, and thank you for standing by. Welcome to Abbott Laboratories' Fourth Quarter 2025 Earnings Conference Call.

TheFly reported on January 9 that Bernstein analyst Lee Hambright raised ABT’s price target to $154 from $150, while maintaining an Outperform rating on the stock. The company noted that U.S.

As of early 2026, the U.S. economy is in a fragile “stagflation-lite” phase, balancing resilient growth against an elevated risk of recession. According to major financial organizations like J.P.

On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA System to treat patients with atrial fibrillation, or AFib.

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.